To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have T-cell NHL and be planning to have high-dose chemotherapy and ASCT.
- Patients may not have received prior romidepsin therapy nor had ASCT or an allogeneic (donated) transplant.
- This study is open to patients age 16 to 70.
For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.